Corient Private Wealth LLC Sells 8,099 Shares of The Cooper Companies, Inc. $COO

Corient Private Wealth LLC cut its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 14.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,318 shares of the medical device company’s stock after selling 8,099 shares during the quarter. Corient Private Wealth LLC’s holdings in Cooper Companies were worth $3,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. J.Safra Asset Management Corp lifted its position in Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 340 shares during the last quarter. CYBER HORNET ETFs LLC bought a new stake in Cooper Companies during the 2nd quarter valued at $36,000. GKV Capital Management Co. Inc. purchased a new stake in Cooper Companies during the 1st quarter valued at $40,000. MUFG Securities EMEA plc bought a new stake in Cooper Companies in the 2nd quarter worth $42,000. Finally, Assetmark Inc. grew its holdings in Cooper Companies by 357.8% in the 2nd quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock worth $44,000 after acquiring an additional 483 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on COO shares. Robert W. Baird upped their price objective on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Citigroup reaffirmed a “neutral” rating and set a $88.00 price target (up previously from $72.00) on shares of Cooper Companies in a research report on Monday, December 8th. Barclays reiterated an “overweight” rating and issued a $91.00 price objective on shares of Cooper Companies in a report on Monday, December 8th. Piper Sandler reissued an “overweight” rating and set a $94.00 target price (up from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Stifel Nicolaus set a $95.00 target price on Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $90.15.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius purchased 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were bought at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the purchase, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This represents a 34.62% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Albert G. White III acquired 10,000 shares of Cooper Companies stock in a transaction that occurred on Tuesday, December 16th. The shares were bought at an average cost of $80.80 per share, with a total value of $808,000.00. Following the transaction, the chief executive officer owned 236,151 shares in the company, valued at $19,081,000.80. This represents a 4.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 16,230 shares of company stock valued at $1,291,233. 1.98% of the stock is owned by company insiders.

Cooper Companies Stock Performance

Shares of COO stock opened at $82.75 on Monday. The company’s fifty day moving average price is $74.70 and its 200-day moving average price is $72.06. The stock has a market cap of $16.22 billion, a PE ratio of 44.02, a price-to-earnings-growth ratio of 2.36 and a beta of 1.05. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $100.24.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. Cooper Companies’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the company posted $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has initiated a stock repurchase program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.